Welcome to our dedicated page for IQVIA Holdings news (Ticker: IQV), a resource for investors and traders seeking the latest updates and insights on IQVIA Holdings stock.
IQVIA Holdings Inc. (symbol: IQV) is a prominent player in the healthcare industry, formed from the merger of Quintiles and IMS Health in 2016. The company operates as a global leader in integrated information and technology solutions, driving advancements in healthcare. With a workforce of approximately 50,000 employees across more than 100 countries, IQVIA is dedicated to helping clients improve their clinical, scientific, and commercial outcomes.
Core Services:
- Research and Development (R&D): IQVIA provides outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. This segment focuses on delivering comprehensive research services to advance medical innovations.
- Technology and Analytics: The company offers aggregated information and technology services, catering to pharmaceutical companies, healthcare providers, payers, and policymakers. IQVIA's data and analytics capabilities extend to clinical trials, including virtual trials, ensuring efficient and effective trial outcomes.
- Contract Sales: IQVIA also maintains a small contract sales business, supporting the commercial needs of its clients.
Recent Achievements and Projects:
IQVIA continues to make significant strides in protecting individual patient privacy while leveraging healthcare data to deliver critical real-world disease and treatment insights. The company's commitment to innovation is evident in its ongoing projects and partnerships aimed at enhancing healthcare outcomes globally.
For more information, visit www.quintilesims.com.
IQVIA Holdings Inc. reported a first-quarter 2023 revenue of $3,652 million, a 2.4% increase year-over-year. GAAP net income stood at $289 million, with diluted earnings per share of $1.53. Adjusted EBITDA reached $851 million, up 10.4% year-over-year. R&D Solutions saw a significant growth in booked contracts, totaling $2.6 billion, leading to a book-to-bill ratio of 1.28x. The contracted backlog for R&D Solutions reached $27.9 billion, a 10.1% year-over-year increase. The company reaffirmed its full-year 2023 guidance, anticipating revenue between $15,150 million and $15,400 million.
IQVIA (NYSE:IQV) has been recognized as a Leader in Customer Experience Platforms (CXP) by Everest Group for its Orchestrated Customer Engagement (OCE) platform. This Salesforce-based solution provides a comprehensive suite of capabilities aimed at enhancing customer engagement for life sciences companies. The OCE platform is praised for its efficiency, actionable analytics, and industry-specific best practices, making it a preferred choice among biopharma clients. Everest Group highlights IQVIA's strong customer engagement capabilities as a key differentiator in a competitive landscape. The recognition underscores IQVIA's commitment to delivering innovative analytics and technology solutions that support clinical development and commercialization in the life sciences sector.
FAQ
What is the current stock price of IQVIA Holdings (IQV)?
What is the market cap of IQVIA Holdings (IQV)?
What is IQVIA Holdings Inc.?
What services does IQVIA offer?
How many employees does IQVIA have?
What is IQVIA's focus in the research and development segment?
What is the role of IQVIA's technology and analytics segment?
Does IQVIA conduct virtual clinical trials?
What industries does IQVIA serve?
How does IQVIA protect patient privacy?
Where can I find more information about IQVIA?
When was IQVIA formed?
